These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 33564073)

  • 1. MNK1 and MNK2 enforce expression of E2F1, FOXM1, and WEE1 to drive soft tissue sarcoma.
    Ke XY; Chen Y; Tham VY; Lin RY; Dakle P; Nacro K; Puhaindran ME; Houghton P; Pang A; Lee VK; Ding LW; Gery S; Hill J; Chen L; Xu L; Koeffler HP
    Oncogene; 2021 Mar; 40(10):1851-1867. PubMed ID: 33564073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitogen-activated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2.
    Waskiewicz AJ; Flynn A; Proud CG; Cooper JA
    EMBO J; 1997 Apr; 16(8):1909-20. PubMed ID: 9155017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reciprocal signaling between mTORC1 and MNK2 controls cell growth and oncogenesis.
    Xie J; Shen K; Jones AT; Yang J; Tee AR; Shen MH; Yu M; Irani S; Wong D; Merrett JE; Lenchine RV; De Poi S; Jensen KB; Trim PJ; Snel MF; Kamei M; Martin SK; Fitter S; Tian S; Wang X; Butler LM; Zannettino ACW; Proud CG
    Cell Mol Life Sci; 2021 Jan; 78(1):249-270. PubMed ID: 32170339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mnk2 and Mnk1 are essential for constitutive and inducible phosphorylation of eukaryotic initiation factor 4E but not for cell growth or development.
    Ueda T; Watanabe-Fukunaga R; Fukuyama H; Nagata S; Fukunaga R
    Mol Cell Biol; 2004 Aug; 24(15):6539-49. PubMed ID: 15254222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacologic Inhibition of MNKs in Acute Myeloid Leukemia.
    Teo T; Lam F; Yu M; Yang Y; Basnet SK; Albrecht H; Sykes MJ; Wang S
    Mol Pharmacol; 2015 Aug; 88(2):380-9. PubMed ID: 26044548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitogen-activated Protein Kinase (MAPK) Interacting Kinases 1 and 2 (MNK1 and MNK2) as Targets for Cancer Therapy: Recent Progress in the Development of MNK Inhibitors.
    Dreas A; Mikulski M; Milik M; Fabritius CH; Brzózka K; Rzymski T
    Curr Med Chem; 2017; 24(28):3025-3053. PubMed ID: 28164761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis and activity of Mnk1 and Mnk2 selective inhibitors containing thieno[2,3-d]pyrimidine scaffold.
    Jin X; Merrett J; Tong S; Flower B; Xie J; Yu R; Tian S; Gao L; Zhao J; Wang X; Jiang T; Proud CG
    Eur J Med Chem; 2019 Jan; 162():735-751. PubMed ID: 30496989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The p38 MAPK-MK2 axis regulates E2F1 and FOXM1 expression after epirubicin treatment.
    de Olano N; Koo CY; Monteiro LJ; Pinto PH; Gomes AR; Aligue R; Lam EW
    Mol Cancer Res; 2012 Sep; 10(9):1189-202. PubMed ID: 22802261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of Mitogen-activated Protein Kinase (MAPK)-interacting Kinase (MNK) Preferentially Affects Translation of mRNAs Containing Both a 5'-Terminal Cap and Hairpin.
    Korneeva NL; Song A; Gram H; Edens MA; Rhoads RE
    J Biol Chem; 2016 Feb; 291(7):3455-67. PubMed ID: 26668315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastases.
    Konicek BW; Stephens JR; McNulty AM; Robichaud N; Peery RB; Dumstorf CA; Dowless MS; Iversen PW; Parsons S; Ellis KE; McCann DJ; Pelletier J; Furic L; Yingling JM; Stancato LF; Sonenberg N; Graff JR
    Cancer Res; 2011 Mar; 71(5):1849-57. PubMed ID: 21233335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of eukaryotic initiation factor 4E (eIF4E) phosphorylation by mitogen-activated protein kinase occurs through modulation of Mnk1-eIF4G interaction.
    Shveygert M; Kaiser C; Bradrick SS; Gromeier M
    Mol Cell Biol; 2010 Nov; 30(21):5160-7. PubMed ID: 20823271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of a Highly Conserved Allosteric Binding Site on Mnk1 and Mnk2.
    Basnet SK; Diab S; Schmid R; Yu M; Yang Y; Gillam TA; Teo T; Li P; Peat T; Albrecht H; Wang S
    Mol Pharmacol; 2015 Nov; 88(5):935-48. PubMed ID: 26268528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Negative regulation of protein translation by mitogen-activated protein kinase-interacting kinases 1 and 2.
    Knauf U; Tschopp C; Gram H
    Mol Cell Biol; 2001 Aug; 21(16):5500-11. PubMed ID: 11463832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneous inhibition of mTOR-containing complex 1 (mTORC1) and MNK induces apoptosis of cutaneous T-cell lymphoma (CTCL) cells.
    Marzec M; Liu X; Wysocka M; Rook AH; Odum N; Wasik MA
    PLoS One; 2011; 6(9):e24849. PubMed ID: 21949767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update on the Development of MNK Inhibitors as Therapeutic Agents.
    Xu W; Kannan S; Verma CS; Nacro K
    J Med Chem; 2022 Jan; 65(2):983-1007. PubMed ID: 34533957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and biological evaluation of 4-aniline-thieno[2,3-d]pyrimidine derivatives as MNK1 inhibitors against renal cell carcinoma and nasopharyngeal carcinoma.
    Zhang M; Jiang L; Tao J; Pan Z; He M; Su D; He G; Jiang Q
    Bioorg Med Chem; 2019 Jun; 27(11):2268-2279. PubMed ID: 31014565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of arsenic trioxide-induced cellular responses by Mnk1 and Mnk2.
    Dolniak B; Katsoulidis E; Carayol N; Altman JK; Redig AJ; Tallman MS; Ueda T; Watanabe-Fukunaga R; Fukunaga R; Platanias LC
    J Biol Chem; 2008 May; 283(18):12034-42. PubMed ID: 18299328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The mitogen-activated protein kinase signal-integrating kinase Mnk2 is a eukaryotic initiation factor 4E kinase with high levels of basal activity in mammalian cells.
    Scheper GC; Morrice NA; Kleijn M; Proud CG
    Mol Cell Biol; 2001 Feb; 21(3):743-54. PubMed ID: 11154262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of mammalian target of rapamycin induces phosphatidylinositol 3-kinase-dependent and Mnk-mediated eukaryotic translation initiation factor 4E phosphorylation.
    Wang X; Yue P; Chan CB; Ye K; Ueda T; Watanabe-Fukunaga R; Fukunaga R; Fu H; Khuri FR; Sun SY
    Mol Cell Biol; 2007 Nov; 27(21):7405-13. PubMed ID: 17724079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacologic co-inhibition of Mnks and mTORC1 synergistically suppresses proliferation and perturbs cell cycle progression in blast crisis-chronic myeloid leukemia cells.
    Teo T; Yu M; Yang Y; Gillam T; Lam F; Sykes MJ; Wang S
    Cancer Lett; 2015 Feb; 357(2):612-23. PubMed ID: 25527453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.